sacituzumab
gilead sciences
['sacitu, govi', 'sacituzumab', 'breast']
new study results in #breastcancer at #esmo22: significant improvement in overall survival (os) results seen in phase 3 tropics study. sacituzumab govitecan improved os from 11.2 months to 14.4 months compared to treatment of choice chemo. cc: 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090